Is hydralazine (direct vasodilator) dialyzable?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Hydralazine Dialyzable?

No, hydralazine is not effectively removed by dialysis due to its high protein binding (87%) and extensive hepatic metabolism, making dose adjustments for dialysis unnecessary.

Pharmacokinetic Properties Preventing Dialyzability

The FDA drug label clearly states that hydralazine has 87% binding to human plasma protein 1. This high degree of protein binding is the primary reason hydralazine cannot be effectively removed by hemodialysis, as dialysis membranes cannot efficiently clear protein-bound drugs.

Additionally, hydralazine undergoes extensive hepatic metabolism and is excreted mainly in the form of metabolites in the urine rather than as unchanged drug 1. This metabolic pathway further reduces the likelihood of significant drug removal during dialysis sessions.

Clinical Implications in Dialysis Patients

  • No dose adjustment is required for patients on maintenance dialysis, as the drug is not significantly removed during dialysis sessions 1

  • Hydralazine can be safely used in patients with end-stage kidney disease on dialysis, with recent data showing potential cardiovascular benefits in this population 2

  • The drug's half-life of 3 to 7 hours and its metabolism are not significantly altered by renal impairment, as elimination depends primarily on hepatic pathways rather than renal excretion 1, 3

Practical Considerations

  • Timing of administration does not need to be coordinated with dialysis sessions, as the drug will not be removed during treatment 1

  • The combination of hydralazine-isosorbide dinitrate has shown efficacy in dialysis patients with heart failure, with lower all-cause mortality rates compared to non-users 2

  • Monitor for the drug's expected effects (reflex tachycardia, blood pressure reduction) regardless of dialysis timing, as pharmacodynamic responses remain intact 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.